Mylan Net Income 2006-2018 | MYL

Current and historical net income for Mylan (MYL) from 2006 to 2018. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for. Mylan net income for the twelve months ending June 30, 2018 was $0.457B. Mylan net income for the three months ending June 30, 2018 was $0.038B, representing a 87.37% decline from the same quarter last year.
Mylan Annual Net Income
(Millions of US $)
2017 $696
2016 $480
2015 $848
2014 $929
2013 $624
2012 $641
2011 $537
2010 $224
2009 $94
2008 $-335
2007 $-1,164
2007 $217
2006 $185
2005 $204
Mylan Quarterly Net Income
(Millions of US $)
Q2 2018 $38
Q1 2018 $87
Q4 2017 $244
Q3 2017 $88
Q2 2017 $297
Q1 2017 $66
Q4 2016 $418
Q3 2016 $-120
Q2 2016 $168
Q1 2016 $14
Q4 2015 $195
Q3 2015 $429
Q2 2015 $168
Q1 2015 $57
Q4 2014 $189
Q3 2014 $499
Q2 2014 $125
Q1 2014 $116
Q4 2013 $180
Q3 2013 $159
Q2 2013 $178
Q1 2013 $107
Q4 2012 $162
Q3 2012 $211
Q2 2012 $139
Q1 2012 $129
Q4 2011 $129
Q3 2011 $157
Q2 2011 $146
Q1 2011 $104
Q4 2010 $3
Q3 2010 $108
Q2 2010 $51
Q1 2010 $61
Q4 2009 $4
Q3 2009 $-40
Q2 2009 $58
Q1 2009 $71
Q4 2008 $-55
Q3 2008 $182
Q2 2008 $-16
Q1 2008 $-447
Q4 2007 $-1,323
Q3 2007 $150
Q2 2007 $80
Q1 2007 $-71
Q4 2006 $135
Q3 2006 $78
Q2 2006 $76
Q1 2006 $0
Q4 2005 $48
Q3 2005 $36
Q2 2005 $43
Q1 2005 $0
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $19.354B $11.908B
Mylan NV is a pharmaceutical company. The company develops, licenses, manufactures, markets and distributes generic and specialty pharmaceuticals. It operates primarily in the United States, Canada, Europe, the Middle East, Africa, India, Australia, Japan and New Zealand. Mylan NV, formerly known as Mylan Inc., is based in Canonsburg, Pennsylvania.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $62.549B 10.73
Teva Pharmaceutical Industries (TEVA) Israel $22.320B 6.24
Bausch Health Cos (BHC) Canada $7.455B 5.57
Dr Reddy's Laboratories (RDY) India $5.335B 23.83
Mallinckrodt Public Limited Company (MNK) United Kingdom $2.637B 4.48
Akorn (AKRX) United States $2.348B 11.63
Supernus Pharmaceuticals (SUPN) United States $2.271B 24.30
Assembly Biosciences (ASMB) United States $1.006B 0.00
Amphastar Pharmaceuticals (AMPH) United States $0.816B 117.53
CymaBay Therapeutics (CBAY) United States $0.718B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.637B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.613B 0.00
Homology Medicines (FIXX) United States $0.587B 0.00
Voyager Therapeutics (VYGR) United States $0.574B 0.00
Corium (CORI) United States $0.336B 0.00
Teligent (TLGT) United States $0.223B 0.00
Sol-Gel Technologies (SLGL) Israel $0.119B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.116B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.077B 0.00
Versartis (VSAR) United States $0.060B 0.00
Aevi Genomic Medicine (GNMX) United States $0.058B 0.00
Evoke Pharma (EVOK) United States $0.040B 0.00
Pernix Therapeutics Holdings (PTX) United States $0.022B 0.00
Acasti Pharma (ACST) Canada $0.017B 0.00
China Pharma Holdings (CPHI) China $0.010B 0.00
Agile Therapeutics (AGRX) United States $0.009B 0.00